All In Biotech

Drug Trial Radar · NCT04291248

A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

A Randomized, Open-label , Multi-cohort, Multicenter, Phase II Study of Anlotinib Combined With AK105 Injection in Subjects With MSI-H or dMMR Advanced Solid Tumor

Last checked: Nov 19, 2026Latest source record: Mar 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

138

Planned (sponsor's estimate)

Start

Mar 2020

Primary completion

Dec 2022

Study completion Dec 2022

Sponsor

Sponsor type
Industry
First posted
Mar 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the efficacy and safety of Anlotinib combined with AK105 injection or AK105 monotherapy in subjects with MSI-H or dMMR advanced solid tumors. In this study, 138 subjects will be enrolled, and those who met the admission criteria will divide into cohort 1 (anlotinib combined with AK105) and cohort 2 (AK105 ). The first phase of this study is a randomized, open-label, parallel-controlled, multicenter design, in which 30 subjects are randomly enrolled in two cohorts. The second phase is to continue enrollment of cohort 1 or cohort 2 when which cohort has the better clinical benefit than the other one.

Conditions

  • MSI-H or dMMR Advanced Solid Tumors

Interventions

  • AK105Drug

    AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.

  • AnlotinibDrug

    A multi-target receptor tyrosine kinase inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR) assessed by Independent Review Committee (IRC)Time frame: up to 96 weeks

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China

  • Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China

  • Chinese Academy of Medical Sciences, Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Peking University International Hospital

    Beijing, Beijing Municipality, China

  • The Third Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of The PLA Air Force Medical University

    Xi’an, Shanxi, China

  • Shanxi Cancer Hospital

    Xi’an, Shanxi, China

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.